What is the mechanism of resistance to eculizumab?

Jul 14, 2017 ... What is already known about this topic? Eculizumab (Soliris, Alexion Pharmaceuticals), a terminal complement inhibitor, is associated with a ... A specific anti-complement treatment (eculizumab; its brand name is Soliris) ... If eculizumab is started, how long does it need to be continued? When a ... Feb 12, 2025 ... These studies suggest that eculizumab and ravulizumab are safe and effective treatments for people with AQP4-Ab+ NMOSD. The treatment is given once a week at a dose of 600 mg for the first 4 weeks, then 900 mg every 2 weeks from the fifth week onwards. A few patients require a ... May 28, 2024 ... The US Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare ... Jun 2, 2024 ... Both eculizumab and efgartigimod provide more treatment benefits to patients with generalized myasthenia gravis compared with conventional immunosuppressive ... Feb 22, 2023 ... This study demonstrates that the majority of patients benefit from eculizumab when adhering to the indications as formulated in the Dutch PNH guideline. Eculizumab injection is used to treat a type of blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Eculizumab is an oral medication designed to block the action of endothelin, a natural substance in the body that narrows blood vessels. By inhibiting ... In this way Soliris improves anaemia, tiredness, and other signs and symptoms of PNH. Patients with aHUS have an inflammatory condition which affects the blood ...